

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺 诚 健 华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

2026 QUARTERLY REPORT FOR THE THIRD QUARTER

This announcement is made by InnoCare Pharma Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

2026 QUARTERLY REPORT FOR THE THIRD QUARTER

Reference is made to the “InnoCare Pharma Limited 2026 Third Quarterly Report” (the “**2026 Third Quarterly Report**”) published by the Company on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2026 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2026 Third Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People’s Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 26 October 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.

Stock Code: 688428

Ticker Symbol: InnoCare

InnoCare Pharma Limited

2026 THIRD QUARTERLY REPORT

The board of directors and all directors of the Company affirm that this announcement contains no false records or misleading statements or material omissions and that they are responsible for the truthfulness, accuracy, and completeness of its contents in accordance with the laws.

IMPORTANT NOTICE:

The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The person in charge of the Company, person in charge of accounting function and person in charge of the Accounting Department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

Whether the third quarterly financial statements have been audited

☐Yes ☒No

MANAGEMENT PERFORMANCE REVIEW

The management of InnoCare Pharma Limited (the “Company”) commented, “The Company is a high-tech innovative biopharmaceutical enterprise driven by outstanding independent research and development capabilities, possessing comprehensive research and development, manufacturing and commercialization abilities. It focuses on areas with significant unmet clinical needs such as oncology and autoimmune diseases, developing drugs with breakthrough potential that are either first-in-class or best-in-class on a global scale.

From January to September 2026, the Company recorded total operating revenue of RMB2.099 billion, representing an increase of 88.21% as compared to the same period of last year, among which revenue from sales of drugs reached RMB1.449 billion, representing an increase of 41.47% as compared to the same period of last year. The increase in operating revenue was primarily driven by continued volume growth of the core product orelabrutinib, new sales contributions from tafasitamab and

zurletrectinib, and the achievement of subsequent milestone payments under the license agreement between the Company and Zenas BioPharma, Inc. (“Zenas”). The Company remained profitable in the third quarter, with a net profit of RMB648 million from January to September 2026, marking a turnaround from a loss as compared to the same period of last year. With a mature commercialization system and a research and development pipeline progressing smoothly, the Company is poised to maintain high-quality growth in the future.

From January to September 2026, the Company recorded net cash flows generated from operating activities of RMB220 million, turning positive from negative year-on-year, which was mainly attributable to the increased revenue from sales of drugs and license income, and the Company’s operating cash flow profile continued to improve.

Leveraging its solid financial position and continuously enhancing cash flow generation capacity, the Company will continue to accelerate the development of various pipeline projects in an effort to provide more and better treatment options for patients in China and around the world.”

I. KEY FINANCIAL INFORMATION

(I) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Items	The reporting period	Increase/decrease during the reporting period compared with the same period of last year (%)	From the beginning of the year to the end of the reporting period	Increase/decrease from the beginning of the year to the end of the reporting period compared with the same period of last year (%)
Operating revenue	962,047,455.35	150.60	2,099,104,519.71	88.21
Among which: revenue from sales of drugs	530,540,562.33	38.59	1,448,682,600.73	41.47
Total profit	412,708,013.16	N/A	659,852,698.94	N/A
Net profit attributable to shareholders of the listed company	409,342,363.89	N/A	655,698,255.66	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	398,972,090.05	N/A	586,038,239.89	N/A
Net cash flows generated from operating activities	N/A	N/A	219,614,982.93	N/A
Basic earnings per share (RMB/share)	0.24	N/A	0.39	N/A
Diluted earnings per share (RMB/share)	0.24	N/A	0.38	N/A
Weighted average return on equity (%)	5.16	N/A	8.25	N/A
Total R&D expenditure	287,978,898.44	27.23	785,052,775.72	16.12

R&D expenditure as a percentage of operating revenue (%)	29.93	Decrease of 29.03 percentage points	37.40	Decrease of 23.21 percentage points
	As at the end of the reporting period	As at the end of the last year		Increase/decrease as at the end of the reporting period compared with the end of the last year (%)
Total assets	11,475,717,069.38	10,823,600,850.70		6.02
Owners' equity attributable to shareholders of the listed company	8,196,520,499.00	7,726,823,182.19		6.08

Note: The “reporting period” refers to the three-month period from the beginning of the current quarter to the end of the current quarter. The same applies hereinafter.

(II) Non-recurring profits and losses items and amounts

✓Applicable □Not applicable

Unit: RMB Currency: Renminbi

Non-recurring profits and losses items	Amount for the reporting period	Amount from the beginning of the year to the end of the reporting period	Description
Profits and losses on disposal of non-current assets, including the write-off portion of asset impairment provisions that have been made	32.26	187,187.48	
Government grants included in current profits and losses (excluding those closely related to the Company's normal course of business operations, in compliance with national policies and regulations, and have a continuous impact on the Company's profits and losses according to established standards)	864,214.10	28,624,559.55	
Profits and losses arising from changes in fair value of financial assets and financial liabilities held by a non-financial enterprise, and profits and losses arising from disposal of financial assets and financial liabilities, except for effective hedging business related to the Company's normal operations	13,279,324.71	50,492,613.21	
Other non-operating income and expenses other than the above items	216,127.16	391,276.44	
Less: Effect on income tax	3,988,923.89	9,989,550.41	
Effect on minority interests (after tax)	500.50	46,070.50	
Total	10,370,273.84	69,660,015.77	

Note: Non-recurring profits and losses items were recognized by the Company in compliance with the requirements of the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses” (CSRC Announcement [2023] No. 65).

Reasons should be provided for identifying items not listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and

Losses” as non-recurring profits and losses items with significant amounts, as well as for defining the non-recurring profits and losses items set out in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses” as recurring profits and losses items.

☐Applicable ☒Not applicable

(III) Changes in key accounting data and financial indicators and the reasons therefor

☒Applicable ☐Not applicable

Item	Percentage change (%)	Main reason
Operating revenue during the reporting period	150.60	This was primarily driven by continued volume growth of the core product orelabrutinib, new contributions from tafasitamab and zurletrectinib, and the achievement of subsequent milestone payments under the license agreement between the Company and Zenas during the reporting period and from the beginning of the year to the end of the reporting period
Revenue from sales of drugs during the reporting period	38.59	
Operating revenue from the beginning of the year to the end of the reporting period	88.21	
Revenue from sales of drugs from the beginning of the year to the end of the reporting period	41.47	
Total profit during the reporting period	N/A	This was primarily due to the significant increase in operating revenue during the reporting period and from the beginning of the year to the end of the reporting period, as well as the profit during the reporting period compared to the loss in the same period of last year
Net profit attributable to shareholders of the listed company during the reporting period	N/A	
Net profit attributable to shareholders of the listed company after deducting non- recurring profits and losses during the reporting period	N/A	
Basic earnings per share (RMB/share) during the reporting period	N/A	
Diluted earnings per share (RMB/share) during the reporting period	N/A	
Weighted average return on equity (%) during the reporting period	N/A	
R&D expenditure as a percentage of operating revenue (%) during the reporting period	Decrease of 29.03 percentage points	
Total profit from the beginning of the year to the end of the reporting period	N/A	

Net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period	N/A	
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses from the beginning of the year to the end of the reporting period	N/A	
Basic earnings per share (RMB/share) from the beginning of the year to the end of the reporting period	N/A	
Diluted earnings per share (RMB/share) from the beginning of the year to the end of the reporting period	N/A	
Weighted average return on equity (%) from the beginning of the year to the end of the reporting period	N/A	
R&D expenditure as a percentage of operating revenue (%) from the beginning of the year to the end of the reporting period	Decrease of 23.21 percentage points	
Net cash flows generated from operating activities from the beginning of the year to the end of the reporting period	N/A	This was mainly due to increased collections driven by the growth in revenue during the reporting period and from the beginning of the year to the end of the reporting period, as well as the positive net cash flows generated from operating activities compared to a negative balance in the same period of last year

II. SHAREHOLDER INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and shareholdings of the top ten shareholders

1. As of the end of the reporting period, the total number of issued shares of the Company was 1,769,688,139 shares, of which 1,496,284,235 shares were issued in Hong Kong, representing approximately 84.55% of the total issued shares of the Company. The number of RMB shares issued on the SSE STAR Market was 273,403,904 shares, representing approximately 15.45% of the total issued shares of the Company.

2. The Hong Kong register of members of the Company consists of HKSCC NOMINEES LIMITED and other registered shareholders, of which HKSCC NOMINEES LIMITED held approximately 99.999% of the Company's Hong Kong shares on behalf of non-registered shareholders, and approximately 0.001% of the Company's Hong Kong shares were held by other registered shareholders.

3. Shares held by HKSCC NOMINEES LIMITED are held on behalf of various customers. According to the relevant shareholder equity disclosure rules of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, shareholders holding 5% or more of the shares are required to disclose their shareholdings, while shareholders holding less than 5% are not required to proactively disclose their shareholdings. The Company is unable to obtain the names and shareholding percentages of overseas shareholders holding less than 5% through public channels. Thus, the table below presents the shares held by HKSCC NOMINEES LIMITED after excluding the shares held by HHLR Fund, L.P. and its persons acting in concert, Sunny View Holdings Limited and the family of Renbin Zhao, and Sunland BioMed Ltd and the family of Jisong Cui, respectively based on the disclosure information in declaration submitted by shareholders on the Hong Kong Stock Exchange as of the end of the reporting period.

4. As of the end of the reporting period, the shareholdings of the top ten shareholders are listed based on the disclosure information in declaration submitted by the relevant shareholders to the Hong Kong Stock Exchange and the A share register provided by CSDC. The nature of A shareholdings is reported in accordance with the categories of holders in the A share register of CSDC.

Unit: share

Total number of ordinary shareholders as at the end of the reporting period		21,481	Total number of preferred shareholders whose voting rights have been restored as at the end of the reporting period (if any)				
Shareholdings of the top ten shareholders (excluding lending shares for refinancing)							
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding (%)	Number of restricted shares held	Number of restricted shares (including lending shares for refinancing)	Pledged, marked or frozen	
						Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	1,026,230,937	57.9894	-	-	Unknown	-
HHLR Fund, L.P. and its persons acting in concert	Overseas legal person	208,671,222	11.7914	-	-	Unknown	-
Sunny View Holdings Limited and the family of Renbin Zhao	Overseas legal person	136,017,893	7.6860	-	-	Nil	-
	Overseas natural person						
Sunland BioMed Ltd and the family of Jisong Cui	Overseas legal person	122,864,032	6.9427	-	-	Nil	-
	Overseas natural person						
Hong Kong Securities Clearing Company Limited	Others	13,484,407	0.7620	-	-	Nil	-
China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment	Others	11,678,453	0.6599	-	-	Nil	-

InnoCare Pharma Limited 2026 THIRD QUARTERLY REPORT

Fund							
Genlong Luo	Domestic natural person	6,088,000	0.3440	-	-	Nil	-
Xiaofa Chen	Domestic natural person	6,061,999	0.3425	-	-	Nil	-
Bank of China Limited – E Fund Healthcare Industry Hybrid Securities Investment Fund	Others	6,058,539	0.3424	-	-	Nil	-
China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund	Others	5,559,939	0.3142	-	-	Nil	-
Shareholdings of the top ten unrestricted shareholders (excluding lending shares for refinancing)							
Name of shareholder		Number of unrestricted outstanding shares held		Type and number of shares			
				Type		Number	
HKSCC NOMINEES LIMITED		1,026,230,937		Others		1,026,230,937	
HHLR Fund, L.P. and its persons acting in concert		208,671,222		Others		208,671,222	
Sunny View Holdings Limited and the family of Renbin Zhao		136,017,893		Others		136,017,893	
Sunland BioMed Ltd and the family of Jisong Cui		122,864,032		Others		122,864,032	
Hong Kong Securities Clearing Company Limited		13,484,407		RMB-denominated ordinary shares		13,484,407	
China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund		11,678,453		RMB-denominated ordinary shares		11,678,453	
Genlong Luo		6,088,000		RMB-denominated ordinary shares		6,088,000	
Xiaofa Chen		6,061,999		RMB-denominated ordinary shares		6,061,999	
Bank of China Limited – E Fund Healthcare Industry Hybrid Securities Investment Fund		6,058,539		RMB-denominated ordinary shares		6,058,539	
China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund		5,559,939		RMB-denominated ordinary shares		5,559,939	
Description of the connected relationships among, or concerted actions taken by the above shareholders		The Company is not aware of whether the above other shareholders have other related relationships or concerted action relationships					
Description of the top ten shareholders and the top ten unrestricted shareholders involved in margin financing and securities lending and refinancing businesses (if any)		Nil					

Involvement of shareholders with shareholdings of more than 5%, top ten shareholders and top ten unrestricted

shareholders in lending shares for refinancing businesses

☐Applicable ☒Not applicable

Changes of top ten shareholders and top ten unrestricted shareholders as compared with the previous period due to lending/returning shares for refinancing

☐Applicable ☒Not applicable

III. OTHER REMINDERS

Other important information about the operation of the Company during the reporting period to which investors should pay attention

☐Applicable ☒Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinions

□Applicable √Not applicable

(II) Financial statements

Consolidated balance sheet

30 September 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	30 September 2026	31 December 2025
Current assets:		
Cash and bank balances	5,856,618,971.31	7,072,287,570.25
Financial assets held for trading	631,364,229.03	-
Accounts receivable	643,448,552.29	502,876,484.30
Prepayments	62,471,953.73	55,363,555.79
Other receivables	1,274,458.59	1,023,083.75
Inventories	225,891,147.92	162,869,393.59
Non-current assets due within one year	435,044,763.89	108,266,458.00
Other current assets	1,194,216,499.03	159,435,900.95
Total current assets	9,050,330,575.79	8,062,122,446.63
Non-current assets:		
Long-term equity investments	1,918,931.30	2,704,223.73
Investments in other equity instruments	1,238,823,312.54	1,173,992,348.80
Other non-current financial assets	23,721,028.94	24,802,834.88
Fixed assets	552,021,508.82	588,282,163.13
Construction in progress	177,430,558.61	115,012,520.68
Right-of-use assets	25,890,900.40	48,964,579.34
Intangible assets	239,754,987.44	248,045,487.72
Goodwill	3,124,706.56	3,124,706.56
Long-term prepaid expenses	28,453,039.34	30,308,238.85
Other non-current assets	134,247,519.64	526,241,300.38
Total non-current assets	2,425,386,493.59	2,761,478,404.07
Total assets	11,475,717,069.38	10,823,600,850.70
Current liabilities:		
Short-term borrowings	802,244,300.87	176,927,924.31
Accounts payable	181,689,238.20	183,698,728.28
Contract liabilities	33,675,500.00	105,432,000.00
Payroll payable	74,572,331.67	78,488,891.35
Taxes payable	84,388,372.38	78,948,938.93
Other payables	154,942,462.07	144,425,839.99
Non-current liabilities due within one year	605,595,585.43	139,496,159.55

InnoCare Pharma Limited 2026 THIRD QUARTERLY REPORT

Other current liabilities	238,168,000.00	476,336,000.00
Total current liabilities	2,175,275,790.62	1,383,754,482.41
Non-current liabilities:		
Long-term borrowings	709,900,000.00	1,001,700,000.00
Lease liabilities	9,879,986.21	19,026,136.31
Long-term payables	-	274,015,713.79
Deferred income	304,213,958.76	289,422,538.71
Deferred income tax liabilities	72,759,689.08	106,509,409.61
Total non-current liabilities	1,096,753,634.05	1,690,673,798.42
Total liabilities	3,272,029,424.67	3,074,428,280.83
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	23,603.84	23,493.75
Capital reserve	12,347,851,409.06	12,199,116,468.68
Less: Treasury shares	19,753,678.96	19,753,678.96
Other comprehensive income	90,387,367.33	425,123,356.65
Retained earnings	-4,221,988,202.27	-4,877,686,457.93
Total equity attributable to owners (or shareholders) of the parent company	8,196,520,499.00	7,726,823,182.19
Minority interests	7,167,145.71	22,349,387.68
Total owners' equity (or shareholders' equity)	8,203,687,644.71	7,749,172,569.87
Total liabilities and owners' equity (or shareholders' equity)	11,475,717,069.38	10,823,600,850.70

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu

Person in charge of the Accounting Department: Yue Tan

Consolidated Statement of Income

January - September 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First three quarters of 2026 (January – September)	First three quarters of 2025 (January – September)
I. Total operating revenue	2,099,104,519.71	1,115,328,393.86
Including: Operating revenue	2,099,104,519.71	1,115,328,393.86
II. Total operating costs	1,529,166,634.45	1,257,702,021.19
Including: Operating costs	184,970,604.66	125,178,009.61
Taxes and surcharges	18,753,035.40	15,820,635.91
Selling expenses	423,295,379.45	385,599,542.61
Administrative expenses	164,290,777.85	130,003,658.42
R&D expenses	785,052,775.72	676,047,531.53
Finance costs	-47,195,938.63	-74,947,356.89
Including: Interest expenses	43,820,397.19	41,713,504.50
Interest income	72,569,690.18	90,929,189.38

InnoCare Pharma Limited 2026 THIRD QUARTERLY REPORT

Add: Other income	39,459,468.66	35,922,627.27
Investment income (loss denoted by “-”)	34,986,655.11	36,526,526.01
Including: Share of profit of associates and joint ventures	-785,292.43	-698,286.98
Gain on derecognition of financial assets measured at amortized cost	-	17,318,112.33
Gain from changes in fair value (loss denoted by “-”)	14,720,665.66	5,094,881.72
Credit impairment loss (loss denoted by “-”)	218,214.23	305,367.03
Impairment loss of assets (loss denoted by “-”)	-48,653.90	-169,364.48
Gain from disposal of assets (loss denoted by “-”)	197,228.08	3,398.23
III. Operating profit (loss denoted by “-”)	659,471,463.10	-64,690,191.55
Add: Non-operating income	547,395.59	511,727.56
Less: Non-operating expenses	166,159.75	861.31
IV. Total profit (total loss denoted by “-”)	659,852,698.94	-64,179,325.30
Less: Income tax expenses	11,505,496.07	7,771,197.73
V. Net profit (net loss denoted by “-”)	648,347,202.87	-71,950,523.03
(I) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	648,347,202.87	-71,950,523.03
2. Net profit from discontinued operations (net loss denoted by “-”)	-	-
(II) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	655,698,255.66	-64,414,920.42
2. Profit or loss attributable to minority shareholders (net loss denoted by “-”)	-7,351,052.79	-7,535,602.61
VI. Other comprehensive income, net of tax	-334,735,989.32	-55,851,426.78
(I) Other comprehensive income attributable to owners of the parent company, net of tax	-334,735,989.32	-55,851,426.78
1. Other comprehensive income not to be reclassified to profit or loss	-334,735,989.32	-55,851,426.78
(1) Changes in the fair value of investments in other equity instruments	-128,677,800.05	-
(2) Translation differences of the financial statements in foreign currency	-206,058,189.27	-55,851,426.78
(II) Other comprehensive income attributable to minority shareholders, net of tax	-	-
VII. Total comprehensive income	313,611,213.55	-127,801,949.81
(I) Total comprehensive income attributable to owners of the parent company	320,962,266.34	-120,266,347.20
(II) Total comprehensive income attributable to minority shareholders	-7,351,052.79	-7,535,602.61
VIII. Earnings per share:		
(I) Basic earnings per share (RMB/share)	0.39	-0.04
(II) Diluted earnings per share (RMB/share)	0.38	-0.04

For business combinations under the same control in the current period, the net profit achieved by the parties

consolidated prior to the consolidation was RMB0.00; the net profit achieved by the parties consolidated in the previous period was RMB0.00.

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu
 Person in charge of the Accounting Department: Yue Tan

Consolidated Statement of Cash Flows

January - September 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First three quarters of 2026 (January – September)	First three quarters of 2025 (January – September)
I. Cash flows generated from operating activities:		
Cash receipts from sales of goods and provision of services	1,826,645,418.27	1,214,209,258.22
Cash received from other operating activities	84,207,168.01	91,258,847.27
Sub-total of cash inflows from operating activities	1,910,852,586.28	1,305,468,105.49
Cash paid for goods and services	869,571,668.47	692,038,648.56
Cash paid to and on behalf of employees	564,677,373.11	482,142,825.85
Cash paid for taxes and levies	127,519,473.58	98,242,937.22
Cash paid for other operating activities	129,469,088.19	117,381,823.91
Sub-total of cash outflows from operating activities	1,691,237,603.35	1,389,806,235.54
Net cash flows generated from operating activities	219,614,982.93	-84,338,130.05
II. Cash flows generated from investment activities:		
Cash received from the disposal of investments	5,323,030,993.69	8,173,973,000.00
Cash received from investment income	65,128,558.11	76,947,370.19
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	200,937.32	5,123.89
Sub-total of cash inflows from investment activities	5,388,360,489.12	8,250,925,494.08
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	100,621,415.32	38,491,510.22
Cash paid for investments	6,470,013,350.00	8,533,933,924.58
Cash paid for other investment activities	11,797,786.60	-
Sub-total of cash outflows from investment activities	6,582,432,551.92	8,572,425,434.80
Net cash flows generated from investment activities	-1,194,072,062.80	-321,499,940.72

III. Cash flows generated from financing activities:		
Cash received from capital contributions	37,294,614.07	18,162,453.91
Cash received from borrowings	901,258,500.04	258,772,323.84
Cash received from other financing activities	-	86,420,746.40
Sub-total of cash inflows from financing activities	938,553,114.11	363,355,524.15
Cash paid for repayment of debts	374,514,709.46	168,420,746.40
Cash paid for distribution of dividends or profits or settlement of interest	28,344,680.82	24,560,756.80
Cash paid for other financing activities	264,051,893.42	32,164,004.22
Sub-total of cash outflows from financing activities	666,911,283.70	225,145,507.42
Net cash flows generated from financing activities	271,641,830.41	138,210,016.73
IV. Effects of changes in exchange rate on cash and cash equivalents	-105,149,478.51	-29,428,276.78
V. Net increase in cash and cash equivalents	-807,964,727.97	-297,056,330.82
Add: Balance of cash and cash equivalents at the beginning of the period	4,506,418,701.18	4,679,466,477.13
VI. Balance of cash and cash equivalents at the end of the period	3,698,453,973.21	4,382,410,146.31

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu
 Person in charge of the Accounting Department: Yue Tan

(III) Adjustment of the financial statements for the beginning of 2026 when the Company implements the new accounting standards or interpretation of standards for the first time

☐Applicable ☒Not applicable

The announcement is hereby made.

Board of directors of InnoCare Pharma Limited
 26 October 2026